PET/CT to Image Hypoxia in Head and Neck Tumours
Conditions
Head and Neck Cancer.
Conditions: official terms
Head and Neck Neoplasms
Conditions: Keywords
cancer, hypoxia, PET scan, CT scan
Study Type
Interventional
Study Phase
Phase 0
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Intervention
Name: PET/CT
Type: Device
Overall Status
Recruiting
Summary
Patients with head and neck cancer will be imaged with PET scan and CT scan in order to determine areas of the tumour that are hypoxic.

It is hypothesized that PET /CT will provide information on hypoxia of the tumors and tumor regions in head and neck cancer patients.
Detailed Description
Patients with head and neck cancer greater than 3 cm will imaged with PET scan and CT scan in order to determine areas of the tumour that are hypoxic. Following surgical removal, samples of the tumour will be evaluated for the expression of hypoxia genes. The preoperative imaging will be compared to the "gold standard" measures of hypoxic response at the level of gene transcription and a new hypoxia marker with the hypoxyprobe detection system (pimonidazole).

Hypothesis: FDG/PET visualization of glycolysis combined with CT visualization of blood flow will correlate with cellular response to hypoxic stress in head and neck tumors and intra-tumor regions. Measurement of relative levels of mRNAs encoding hypoxia response genes will be performed in cells microdissected from the surgical samples. Good correlation between imaging signals and direct molecular measures of hypoxic response in primary human tumors will provide information necessary to develop treatment strategies that employ targeted, increased radiation to hypoxic tumors.

Pimonidazole is an exogenous nitro-imidazole marker, which can be detected through immunohistochemical analysis of frozen sections. It detects cellular hypoxia upon becoming reduced in cells with low oxygen tension, a property that can be detected through antibody mediated detection of the reduced form. It has also shown to reliably and specifically stain hypoxic regions within the tumor, and to correlate well with patient prognosis and treatment outcome.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- All patients with head and neck tumours (>3cm diameter) without bone involvement.

Exclusion Criteria:

- Known allergy to contrast agents

- Poor kidney function (serum creatinine level > 2.0 mg/dL or 177 mmol/L)

- Pregnancy

- Breast-feeding

- Unable to lie supine

- Patient who were biopsied or operated upon within the past month.

- Patient who were treated with chemotherapy or radiation within the past month.

- Tumors that were obscured by artifacts (e.g. tooth fillings) in CT scans.
Location
London Health Science Center
London, Ontario, Canada
Status: Recruiting
Contact: John Yoo, MD - 519-6858457 - john.yoo@lhsc.on.ca
Start Date
January 2007
Completion Date
December 2009
Sponsors
Lawson Health Research Institute
Source
Lawson Health Research Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page